A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma

Gynecologic Oncology

Volumn 124, Issue 2, 2012, Pages 210-215

  Wahner Hendrickson, Andrea E ^a   Oberg, Ann L ^a   Glaser, Gretchen ^a   Camoriano, John K ^c   Peethambaram, Prema P ^a   Colon Otero, Gerardo ^b   Erlichman, Charles ^a   Ivy, S Percy ^d   Kaufmann, Scott H ^a,e   Karnitz, Larry M ^a,e   Haluska, Paul ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

Gemcitabine; Heat shock protein 90; Ovarian cancer; Peritoneal cancer; Phase I II trials; Tanespimycin

Indexed keywords

CA 125 ANTIGEN; GEMCITABINE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; TANESPIMYCIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPNEA; EDEMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DERMATITIS; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; UPREGULATION; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; CELL LINE, TUMOR; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84856023437     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.10.002     Document Type: Article

References (31)

1. M. Taipale, D.F. Jarosz, and S. Lindquist HSP90 at the hub of protein homeostasis: emerging mechanistic insights Nat Rev Mol Cell Biol 11 2010 515 528
2. L. Whitesell, and S.L. Lindquist HSP90 and the chaperoning of cancer Nat Rev Cancer 5 2005 761 772 (Pubitemid 41400776)
3. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers Targeting the dynamic HSP90 complex in cancer Nat Rev Cancer 10 2010 537 549
4. R.C. Schnur, M.L. Corman, R.J. Gallaschun, B.A. Cooper, M.F. Dee, and J.L. Doty Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives J Med Chem 38 1995 3806 3812
5. T.W. Schulte, and L.M. Neckers The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin Cancer Chemother Pharmacol 42 1998 273 279 (Pubitemid 28393843)
6. Z.Q. Yuan, M. Sun, R.I. Feldman, G. Wang, X. Ma, and C. Jiang Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 19 2000 2324 2330 (Pubitemid 30307208)
7. N. Gao, D.C. Flynn, Z. Zhang, X.S. Zhong, V. Walker, and K.J. Liu G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells Am J Physiol Cell Physiol 287 2004 C281 C291
8. H.Y. Zhang, P.N. Zhang, and H. Sun Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy Eur J Obstet Gynecol Reprod Biol 146 2009 81 86
9. P.A. van Dam, I.B. Vergote, D.G. Lowe, J.V. Watson, P. van Damme, and J.C. van der Auwera Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma J Clin Pathol 47 1994 914 919
10. M.P. Goetz, D. Toft, J. Reid, M. Ames, B. Stensgard, and S. Safgren Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer J Clin Oncol 23 2005 1078 1087 (Pubitemid 46202262)
11. U. Banerji, A. O'Donnell, M. Scurr, S. Pacey, S. Stapleton, and Y. Asad Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 23 2005 4152 4161 (Pubitemid 46211321)
12. R.K. Ramanathan, D.L. Trump, J.L. Eiseman, C.P. Belani, S.S. Agarwala, and E.G. Zuhowski Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers Clin Cancer Res 11 2005 3385 3391 (Pubitemid 40627891)
13. G.S. Nowakowski, A.K. McCollum, M.M. Ames, S.J. Mandrekar, J.M. Reid, and A.A. Adjei A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer Clin Cancer Res 12 2006 6087 6093 (Pubitemid 44703773)
14. R.K. Ramanathan, M.J. Egorin, J.L. Eiseman, S. Ramalingam, D. Friedland, and S.S. Agarwala Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers Clin Cancer Res 13 2007 1769 1774 (Pubitemid 46952944)
15. D.B. Solit, S.P. Ivy, C. Kopil, R. Sikorski, M.J. Morris, and S.F. Slovin Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer Clin Cancer Res 13 2007 1775 1782 (Pubitemid 46952945)
16. J. Hubbard, C. Erlichman, D.O. Toft, R. Qin, B.A. Stensgard, and S. Felten Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors Invest New Drugs 29 3 2011 Jun 473 480
17. M. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer Gynecol Oncol 90 2003 593 596
18. W.C. Fowler Jr. , and L. Van Le Gemcitabine as a single-agent treatment for ovarian cancer Gynecol Oncol 90 2003 S21 S23
19. M.J. O'Connell, and K.A. Cimprich G2 damage checkpoints: what is the turn-on? J Cell Sci 118 2005 1 6 (Pubitemid 40277099)
20. L.M. Karnitz, K.S. Flatten, J.M. Wagner, D. Loegering, J.S. Hackbarth, and S.J. Arlander Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival Mol Pharmacol 68 2005 1636 1644 (Pubitemid 41654347)
21. S.J. Arlander, A.K. Eapen, B.T. Vroman, R.J. McDonald, D.O. Toft, and L.M. Karnitz Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress J Biol Chem 278 2003 52572 52577 (Pubitemid 38035854)
22. H.S. Friedman, M.E. Dolan, S.H. Kaufmann, O.M. Colvin, O.W. Griffith, and R.C. Moschel Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan Cancer Res 54 1994 3487 3493 (Pubitemid 24225971)
23. S.H. Kaufmann, P.A. Svingen, S.D. Gore, D.K. Armstrong, Y.C. Cheng, and E.K. Rowinsky Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells Blood 89 1997 2098 2104 (Pubitemid 27132126)
24. S.H. Kaufmann Reutilization of immunoblots after chemiluminescent detection Anal Biochem 296 2001 283 286 (Pubitemid 32868511)
25. A.N. Tse, D.S. Klimstra, M. Gonen, M. Shah, T. Sheikh, and R. Sikorski A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors Clin Cancer Res 14 2008 6704 6711
26. P.G. Richardson, A.Z. Badros, S. Jagannath, S. Tarantolo, J.L. Wolf, and M. Albitar Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma Br J Haematol 150 2010 428 437
27. U.N. Vaishampayan, A.M. Burger, E.A. Sausville, L.K. Heilbrun, J. Li, and M.N. Horiba Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin Clin Cancer Res 16 2010 3795 3804
28. R.A. Mesa, D. Loegering, H.L. Powell, K. Flatten, S.J. Arlander, and N.T. Dai Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine Blood 106 2005 318 327 (Pubitemid 40967208)
29. B. Tillotson, K. Slocum, J. Coco, N. Whitebread, B. Thomas, and K.A. West Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo J Biol Chem 285 2010 39835 39843
30. A.K. McCollum, K.B. Lukasiewicz, C.J. Teneyck, W.L. Lingle, D.O. Toft, and C. Erlichman Cisplatin abrogates the geldanamycin-induced heat shock response Mol Cancer Ther 7 2008 3256 3264
31. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, and L.C. Fritz A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 2003 407 410 (Pubitemid 37187270)